Merck Says PD-L1 Testing Already On The Rise, Setting Stage For First-Line Launch
Executive Summary
Testing for the biomarker has picked up since paradigm changing data in first-line lung cancer was presented at ESMO, management said. Now, with the FDA approval of Keytruda, Merck is focused on establishing a solid lead in a big commercial market.
You may also be interested in...
Merck's Keytruda Reaches Blockbuster Status, But Still Lags In Lung Cancer
Merck’s PD-1 inhibitor Keytruda brought in $1.4bn in 2016 and appears poised to take advantage of first-mover status among immuno-oncology agents in first-line NSCLC.
PD-1 Deep Dive: Lung Cancer Market Braced For Change
Execs speculated during third-quarter earnings calls about the impact of FDA approval for Merck's Keytruda in first-line lung cancer and looked forward to readouts of combination studies, which could soon bring another market shake-up.
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
The latest drug development news and highlights from our FDA Performance Tracker.